{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:21:43Z","timestamp":1785403303459,"version":"3.56.0"},"reference-count":189,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2021,10,3]]},"DOI":"10.1080\/17512433.2021.1949285","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T11:25:45Z","timestamp":1624706745000},"page":"1205-1220","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Recent advances and future perspectives in the pharmacological treatment of<i>Candida auris<\/i>infections"],"prefix":"10.1080","volume":"14","author":[{"given":"Daniele R.","family":"Giacobbe","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnasco","sequence":"additional","affiliation":[{"name":"Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sepulcri","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-7495","authenticated-orcid":false,"given":"Philipp","family":"Koehler","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS K\u00f6ln), Cologne, Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-9740","authenticated-orcid":false,"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2008.00083.x"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2019.06.006"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.901"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14612"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.08.013"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.02.001"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.01.004"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.3390\/jof7030163"},{"key":"cit0010","unstructured":"PubChem. Ibrexafungerp [Internet]. [cited 2021 Apr 5]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/46871657"},{"key":"cit0011","author":"Ghannoum M","journal-title":"Antibiotics (Basel)"},{"key":"cit0012","unstructured":"SCYNEXIS Announces Advancement of Ibrexafungerp\u2019s Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections\u202f: SCYNEXIS, Inc. (SCYX) [Internet]. [cited 2021 Apr 10]. Available from: https:\/\/www.scynexis.com\/news-media\/press-releases\/detail\/226\/scynexis-announces-advancement-of-ibrexafungerps"},{"key":"cit0013","author":"Jim\u00e9nez-Ortigosa C","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz083"},{"key":"cit0015","author":"Pfaller MA","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx422"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.588"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1146"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx010"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02396-16"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105922"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02136-19"},{"key":"cit0023","author":"Berkow EL","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0024","author":"Ghannoum M","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02694-20"},{"key":"cit0026","unstructured":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis [Internet]. [cited 2021 Mar 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03734991"},{"key":"cit0027","unstructured":"Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (Vanish 306) [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03987620"},{"key":"cit0028","unstructured":"Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE) [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04029116"},{"key":"cit0029","unstructured":"Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) [Internet]. [cited 2021 Mar 18].Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03059992"},{"key":"cit0030","unstructured":"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis [Internet]. [cited 2021 Mar 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03672292"},{"key":"cit0031","unstructured":"Juneja D, Singh O, Tarai B, et al. L0028 Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study. In Amsterdam, Netherlands; 2019. [cited 2021 Apr 5]. Available from: https:\/\/www.escmid.org\/guidelines_publications\/escmid_elibrary\/material\/?mid=66635"},{"key":"cit0032","unstructured":"SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp\u2019s Ability to Treat Severe Fungal Infections in the Hospital Setting [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/www.globenewswire.com\/news-release\/2021\/03\/02\/2185158\/0\/en\/SCYNEXIS-Announces-Positive-Results-from-Interim-Analyses-of-Ongoing-Phase-3-Studies-FURI-and-CARES-Demonstrating-Oral-Ibrexafungerp-s-Ability-to-Treat-Severe-Fungal-Infections-in-html"},{"key":"cit0033","author":"Garcia-Effron G","journal-title":"J Fungi (Basel)"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.89"},{"key":"cit0035","author":"Sandison T","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz390"},{"key":"cit0037","unstructured":"Antifungal Susceptibility Testing and Interpretation | candida auris | fungal Diseases | CDC [Internet]. [cited 2021 Mar 22]. Available from: https:\/\/www.cdc.gov\/fungal\/candida-auris\/c-auris-antifungal.html"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.021"},{"key":"cit0039","author":"Helleberg M","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02788"},{"key":"cit0041","author":"Marcos-Zambrano LJ","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0042","author":"Kordalewska M","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0043","author":"T\u00f3th Z","journal-title":"J Fungi (Basel)"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.09.016"},{"key":"cit0045","author":"Lepak AJ","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky153"},{"key":"cit0047","doi-asserted-by":"crossref","unstructured":"Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial. Clin Infect Dis. 2020 Sep 21. doi: 10.1093\/cid\/ciaa1380.","DOI":"10.1093\/cid\/ciaa1380"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000473"},{"key":"cit0049","unstructured":"A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and\/or Invasive Candidiasis [Internet]. [cited 2021 Mar 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03667690"},{"key":"cit0050","unstructured":"A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study) [Internet]. [cited 2021 Mar 18].Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368559"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01817-16"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2018.03.001"},{"key":"cit0053","doi-asserted-by":"crossref","unstructured":"Brand SR, Sobel JD, Nyirjesy P, et al. Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. Clin Infect Dis. 2020 Aug 20. doi: 10.1093\/cid\/ciaa1204.","DOI":"10.1093\/cid\/ciaa1204"},{"key":"cit0054","unstructured":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis [Internet]. [cited 2021 Apr 8]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03562156"},{"key":"cit0055","unstructured":"A Study of Oral VT-1161 for the Treatment of Acute Vaginal Candidiasis (Yeast Infection) in Patients With Recurrent Vaginal Candidiasis (ultraVIOLET) - NCT03840616. [cited 2021 Apr 4];Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03840616"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19224"},{"key":"cit0057","unstructured":"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Moderate to Severe Interdigital Tinea Pedis [Internet]. [cited 2021 Apr 8]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01891305"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-11"},{"issue":"4","key":"cit0059","volume":"6","author":"Shaw KJ","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1390"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1370"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02319-17"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00656-20"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00840-19"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky302"},{"key":"cit0066","first-page":"2018 Mar 27;62(","author":"Zhao M","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01124-20"},{"key":"cit0068","author":"Wiederhold NP","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0069","unstructured":"Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix | amplyx [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/amplyx.com\/amplyx-announces-positive-top-line-data-in-phase-2-clinical-trial-of-novel-antifungal-fosmanogepix\/"},{"key":"cit0070","unstructured":"A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds [Internet]. 2021 Feb [cited 2021 Mar 18].Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04240886"},{"key":"cit0071","unstructured":"An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Patients With Candidemia and\/or Invasive Candidiasis Caused by Candida Auris [Internet]. 2021 Mar [cited 2021 Mar 22].Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04148287"},{"issue":"10","key":"cit0072","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00838-20","volume":"64","author":"Skipper CP","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0073","author":"Aigner M","journal-title":"J Fungi (Basel)"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa016"},{"key":"cit0075","unstructured":"A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB\/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC) [Internet]. clinicaltrials.gov; 2018 Oct [cited 2021 Mar 21]. Report No.: NCT02971007. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02971007"},{"key":"cit0076","unstructured":"A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB\/MAT2203) for the Treatment of Cryptococcal Infection [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03196921"},{"key":"cit0077","unstructured":"A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB\/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02629419"},{"key":"cit0078","author":"Wiederhold NP","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0079","unstructured":"A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of VT-1598 in Healthy Adult Subjects [Internet]. [cited 2021 Apr 8]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04208321"},{"key":"cit0080","author":"Wiederhold NP","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02770-15"},{"issue":"4","key":"cit0082","first-page":"453","volume":"55","author":"Kirsten N","journal-title":"Med Mycol"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00349-16"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13260"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.2174\/092986711794088399"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1128\/EC.00095-14"},{"key":"cit0087","author":"Pathirana RU","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0088","author":"Basso V","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-269860"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202000005"},{"key":"cit0091","author":"Kubiczek D","journal-title":"Antibiotics (Basel)"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.9b02201"},{"key":"cit0093","author":"Rank LA","journal-title":"mSphere"},{"key":"cit0094","author":"Kov\u00e1cs R","journal-title":"Int J Mol Sci"},{"key":"cit0095","author":"Dal Mas C","journal-title":"Biomolecules"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.9b01724"},{"key":"cit0097","author":"Vazquez-Munoz R","journal-title":"Antibiotics (Basel)"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01436"},{"key":"cit0099","author":"Kunyeit L","journal-title":"mBio."},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33199-z"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00397"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1007\/s40475-019-00173-2"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy185"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007460"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3400-x"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00957"},{"key":"cit0107","author":"Reitzel RA","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0108","unstructured":"Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection - NCT02651428. [cited 2021 Apr 5]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02651428"},{"key":"cit0109","unstructured":"Cormedix Inc. demonstrated sensitivity of emerging global health threat CAndida auris to taurolidine[Internet]. cited 2021 Apr 5]. Available from: http:\/\/www.cormedix.com\/cormedix-inc-demonstrates-sensitivity-emerging-global-health-threat-candida-auris-taurolidine\/"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00299-19"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00091-17"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd6919"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02198-19"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55379-1"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1186\/2193-9616-1-3"},{"key":"cit0116","author":"de S\u00e1 NP","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29973-8"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01975-18"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1021\/jm900760k"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.105865"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.005"},{"key":"cit0122","author":"Iyer KR","journal-title":"mBio. 2020 Mar 10;11(2):e03329-19."},{"key":"cit0123","author":"Mamouei Z","journal-title":"mSphere"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-019-2666-6"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58203-3"},{"key":"cit0126","author":"Horn C","journal-title":"Antibiotics (Basel)"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-019-00352-9"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1038\/534314a"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks275"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.414-421.2006"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks353"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S205350"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.07.022"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01890-15"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.072322"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106049"},{"key":"cit0137","author":"Wu Y","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0138","author":"Wall G","journal-title":"J Fungi (Basel)"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1111\/jam.14490"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00083"},{"key":"cit0141","author":"Wall G","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0142","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.597931"},{"key":"cit0143","unstructured":"Eiger Biopharmaceuticals. Hepatitis Delta Virus (HDV) Infection [Internet]. [cited 2021 Mar 21]. Available from:https:\/\/eigerbio.com\/hepatitis-delta"},{"key":"cit0144","unstructured":"FDA Approves First Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-0254-1"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1089\/photob.2018.4604"},{"key":"cit0147","author":"Cheng Y-S","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.171"},{"key":"cit0149","author":"Bidaud AL","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0150","author":"O\u2019Brien B","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0151","author":"Eldesouky HE","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.08.016"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001552"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105901"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2020.1838741"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20183-3"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.107"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.08.030"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.03.086"},{"key":"cit0160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2009.12.035"},{"key":"cit0161","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz057"},{"key":"cit0162","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.68.11.5459-5463.2002"},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku374"},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.007"},{"key":"cit0165","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-20"},{"key":"cit0166","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78588-5"},{"key":"cit0167","volume":"03","author":"Nagy F","year":"2021","journal-title":"bioRxiv"},{"key":"cit0168","author":"Caballero U","journal-title":"Antibiotics"},{"key":"cit0169","author":"Gharehbolagh SA","journal-title":"Mycoses"},{"key":"cit0170","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa394"},{"key":"cit0171","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12746"},{"key":"cit0172","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13054"},{"key":"cit0173","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30609-1"},{"key":"cit0174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.07.008"},{"key":"cit0175","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.131765"},{"key":"cit0176","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06440-11"},{"key":"cit0177","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00485-17"},{"key":"cit0178","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx480"},{"key":"cit0179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.08.017"},{"key":"cit0180","author":"Lepak AJ","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0181","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz178"},{"key":"cit0182","author":"Magnasco L","journal-title":"Microorganisms"},{"key":"cit0183","doi-asserted-by":"crossref","unstructured":"Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017 Jan 15;64(2):134\u2013140.","DOI":"10.1093\/cid\/ciw691"},{"issue":"6","key":"cit0184","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/JCM.00367-15","volume":"53","author":"Kathuria S","year":"2015","journal-title":"J Clin Microbiol"},{"key":"cit0185","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30597-8"},{"key":"cit0186","doi-asserted-by":"publisher","DOI":"10.3201\/eid2509.190262"},{"key":"cit0187","author":"Di Pilato V","journal-title":"J Fungi (Basel)"},{"key":"cit0188","author":"Crea F","journal-title":"Euro Surveill"},{"key":"cit0189","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00414"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2021.1949285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T16:36:57Z","timestamp":1672591017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2021.1949285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":189,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,3]]}},"alternative-id":["10.1080\/17512433.2021.1949285"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2021.1949285","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}